Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 108 articles: HTML format

Single Articles

November 2025
1. BALASUBRAMANIAN A, Marceaux C, Kanwal S, Tarasova I, et al
   Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
   Clin Cancer Res. 2025;31:4644-4654.
   PubMed     Abstract available
   
   
   
2. PECCI F, Li H, Di Federico A, Wu J, et al
   First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy +/- Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC.
   Clin Cancer Res. 2025;31:4802-4813.
   PubMed     Abstract available
   
   
   
3. YANG Y, Nilsson MB, Yu X, Poteete A, et al
   The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.
   Clin Cancer Res. 2025;31:4745-4762.
   PubMed     Abstract available
   
   
   October 2025
4. CHONG CR, Bahcall M, Capelletti M, Kosaka T, et al
   Editor's Note: Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
   Clin Cancer Res. 2025;31:4384.
   PubMed    
   
   
   September 2025
5. GIUDICE AM, Matlaga S, Roth SL, Gladney W, et al
   D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.
   Clin Cancer Res. 2025 Sep 30. doi: 10.1158/1078-0432.CCR-25-0089.
   PubMed     Abstract available
   
   
   
6. CHEN PW, Minocha M, Kong S, Jiang T, et al
   Tarlatamab exposure-efficacy and exposure-safety relationships to inform dose selection in patients with small cell lung cancer (SCLC).
   Clin Cancer Res. 2025 Sep 10. doi: 10.1158/1078-0432.CCR-25-2134.
   PubMed     Abstract available
   
   
   August 2025
7. RIMNER A, Lok BH, Gelblum DY, Kotecha RR, et al
   Phase I Dose Escalation Trial Combining Olaparib and Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer.
   Clin Cancer Res. 2025 Aug 29. doi: 10.1158/1078-0432.CCR-24-4342.
   PubMed     Abstract available
   
   
   
8. GAO R, Lou N, Yang S, Yang M, et al
   Multi-Omics and Single-Cell Insights Reveal a Lysophosphatidic Acid (LPA)-Mediated Resistant Mechanism to Third Generation EGFR-TKI in Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0993.
   PubMed     Abstract available
   
   
   
9. CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
   Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer.
   Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
   PubMed     Abstract available
   
   
   July 2025
10. ZHAO L, Pang Y, Ding Y, Chen J, et al
    68Ga-NK224 PET/CT for Noninvasive Evaluation of PD-L1 Expression and Intertumor Heterogeneity: A Translational Exploratory Study.
    Clin Cancer Res. 2025;31:2989-3001.
    PubMed     Abstract available
    
    
    
11. ROLFO C, O'Brate A, Menzel C, Bruns R, et al
    Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
    Clin Cancer Res. 2025;31:2675-2684.
    PubMed     Abstract available
    
    
    
12. JANG HJ, Patel M, Wang DY, Kang SW, et al
    Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.
    Clin Cancer Res. 2025;31:2639-2654.
    PubMed     Abstract available
    
    
    June 2025
13. GAY CM, Owonikoko TK, Byers LA, Choudhury NJ, et al
    Multidimensional Analysis of B7 homolog 3 (B7-H3) RNA Expression in Small-cell Lung Cancer Molecular Subtypes.
    Clin Cancer Res. 2025 Jun 24. doi: 10.1158/1078-0432.CCR-24-3981.
    PubMed     Abstract available
    
    
    
14. DAVAR D, Eroglu Z, Milhem M, Becerra C, et al
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
    Clin Cancer Res. 2025 Jun 24:OF1-OF9. doi: 10.1158/1078-0432.CCR-25-0806.
    PubMed     Abstract available
    
    
    
15. DAVIES KD
    Finding Rearrangements in the Cell-Free DNA Haystack.
    Clin Cancer Res. 2025;31:2264-2266.
    PubMed     Abstract available
    
    
    
16. PAWELETZ CP, Urvalek A, Ha M, Garg K, et al
    Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples.
    Clin Cancer Res. 2025;31:2406-2412.
    PubMed     Abstract available
    
    
    
17. MACK PC, Redman MW, Tukachinsky H, Kozono DE, et al
    Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study.
    Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-3658.
    PubMed     Abstract available
    
    
    
18. ANDREWS HS, Zariffa N, Nishimura KK, Choi SH, et al
    ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials.
    Clin Cancer Res. 2025;31:2162-2172.
    PubMed     Abstract available
    
    
    May 2025
19. CHENG Y, Wang J, Yu Y, Wang Q, et al
    Phase I/II Study of Tifcemalimab, an Anti-B and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0022.
    PubMed     Abstract available
    
    
    April 2025
20. ZHANG J, Jin Y, Lin H, Deng J, et al
    Amplification of extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3399.
    PubMed     Abstract available
    
    
    
21. HIRSCH FR
    Antibody Drug Conjugates in Non-Small Cell Lung Cancer: Where is the Target and the Biomarker?
    Clin Cancer Res. 2025 Apr 28. doi: 10.1158/1078-0432.CCR-25-0839.
    PubMed     Abstract available
    
    
    
22. ZHOU J, Muluneh B, Wang Z, Yao H, et al
    Leveraging Longitudinal Patient-Reported Outcomes Trajectories to Predict Survival in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 24. doi: 10.1158/1078-0432.CCR-25-0292.
    PubMed     Abstract available
    
    
    
23. PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al
    Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990.
    PubMed     Abstract available
    
    
    
24. JENG MY, Schoenfeld AJ
    Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
    Clin Cancer Res. 2025;31:1381-1382.
    PubMed     Abstract available
    
    
    
25. MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al
    Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
    Clin Cancer Res. 2025;31:1533-1545.
    PubMed     Abstract available
    
    
    March 2025
26. KANDA S, Niho S, Kurata T, Nomura S, et al
    Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
    Clin Cancer Res. 2025 Mar 31. doi: 10.1158/1078-0432.CCR-24-3532.
    PubMed     Abstract available
    
    
    
27. KATAYAMA Y, Yamada T, Tanimura K, Kawachi H, et al
    YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
    Clin Cancer Res. 2025;31:1127-1141.
    PubMed     Abstract available
    
    
    
28. TRONTZAS IP, He M, Wurtz A, Robbins CJ, et al
    Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Mar 6. doi: 10.1158/1078-0432.CCR-24-3347.
    PubMed     Abstract available
    
    
    February 2025
29. CHENG H, Janakiram M, Borczuk A, Lin J, et al
    Editor's Note: HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Clin Cancer Res. 2025;31:788.
    PubMed    
    
    
    
30. WOJTALLA A, Fischer B, Kotelevets N, Mauri FA, et al
    Correction: Targeting the Phosphoinositide 3-Kinase p110-alpha Isoform Impairs Cell Proliferation, Survival, and Tumor Growth in Small Cell Lung Cancer.
    Clin Cancer Res. 2025;31:787.
    PubMed    
    
    
    
31. AGGARWAL RK, Sidoli S, Wang J, Sahu S, et al
    Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation.
    Clin Cancer Res. 2025;31:746-755.
    PubMed     Abstract available
    
    
    
32. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    PubMed     Abstract available
    
    
    
33. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    PubMed     Abstract available
    
    
    January 2025
34. CHIU CL, Zhang D, Zhao H, Wei Y, et al
    Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
    Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028.
    PubMed     Abstract available
    
    
    
35. ZHANG JT, Liu SY, Gao X, Liu SM, et al
    Follow-Up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Jan 24. doi: 10.1158/1078-0432.CCR-24-2909.
    PubMed     Abstract available
    
    
    
36. KATO R, Solanki HS, Ozakinci H, Desai B, et al
    In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C--mutant non-small cell lung cancer.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-3714.
    PubMed     Abstract available
    
    
    
37. CAPPUZZO F, Ricciuti B, Delmonte A, Bonanno L, et al
    MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
    Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077.
    PubMed     Abstract available
    
    
    
38. SMEENK MM, van Diessen JNA, Boellaard TN, Hartemink KJ, et al
    Tremelimumab plus durvalumab prior to chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer: the Induction trial.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-3476.
    PubMed     Abstract available
    
    
    
39. ROSNER S, Connor S, Sanber K, Zahurak M, et al
    Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.
    Clin Cancer Res. 2025;31:339-351.
    PubMed     Abstract available
    
    
    
40. REINECKE JB, Jimenez Garcia L, Gross AC, Cam M, et al
    Aberrant Activation of Wound-Healing Programs within the Metastatic Niche Facilitates Lung Colonization by Osteosarcoma Cells.
    Clin Cancer Res. 2025;31:414-429.
    PubMed     Abstract available
    
    
    
41. DALL'OLIO FG, Zrafi W, Roelants V, Ambrosini V, et al
    Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates.
    Clin Cancer Res. 2025;31:352-364.
    PubMed     Abstract available
    
    
    
42. NEGRAO MV, Paula AG, Molkentine D, Hover L, et al
    Impact of co-mutations and transcriptional signatures in non-small cell lung cancer patients treated with adagrasib in the KRYSTAL-1 trial.
    Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-2310.
    PubMed     Abstract available
    
    
    
43. MEADOR CB, Digumarthy SR, Yeap BY, Hung YP, et al
    Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
    Clin Cancer Res. 2025;31:25-34.
    PubMed     Abstract available
    
    
    
44. SCHULER M
    Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-1441.
    PubMed     Abstract available
    
    
    December 2024
45. LEE S, Hamid O, Jotte R, Zakharia Y, et al
    Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478.
    PubMed     Abstract available
    
    
    
46. AOKAGE K, Koyama S, Kumagai S, Nomura K, et al
    Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).
    Clin Cancer Res. 2024;30:5584-5592.
    PubMed     Abstract available
    
    
    
47. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    PubMed     Abstract available
    
    
    
48. VON ITZSTEIN MS, Burns TF, Dowell JE, Horn L, et al
    Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.
    Clin Cancer Res. 2024 Dec 9. doi: 10.1158/1078-0432.CCR-24-1722.
    PubMed     Abstract available
    
    
    November 2024
49. ALTAN M, Lopes G, Hiltermann TJN, Govindan R, et al
    Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591.
    PubMed     Abstract available
    
    
    
50. SOO RA, Dafni U, Han JY, Cho BC, et al
    ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial.
    Clin Cancer Res. 2024;30:5180-5191.
    PubMed     Abstract available
    
    
    October 2024
51. STEWART CA, Diao L, Xi Y, Wang R, et al
    YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities.
    Clin Cancer Res. 2024;30:4743-4754.
    PubMed     Abstract available
    
    
    
52. VERKERK K, van der Wel TJWT, Zeverijn LJ, Geurts BS, et al
    Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol.
    Clin Cancer Res. 2024 Oct 1. doi: 10.1158/1078-0432.CCR-24-1925.
    PubMed     Abstract available
    
    
    
53. LIZARDO MM, Hughes C, Huang YZ, Shyp T, et al
    Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis.
    Clin Cancer Res. 2024;30:4464-4481.
    PubMed     Abstract available
    
    
    September 2024
54. MORGENSZTERN D, Ready N, Johnson ML, Dowlati A, et al
    A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
    Clin Cancer Res. 2024 Sep 17. doi: 10.1158/1078-0432.CCR-24-1547.
    PubMed     Abstract available
    
    
    
55. VOKES NI, Le X, Yap TA
    PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
    Clin Cancer Res. 2024;30:3968-3970.
    PubMed     Abstract available
    
    
    
56. CHOI Y, Dharia NV, Jun T, Chang J, et al
    Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.
    Clin Cancer Res. 2024;30:3788-3797.
    PubMed     Abstract available
    
    
    
57. EL ZARIF T, Meador CB, Qiu X, Seo JH, et al
    Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.
    Clin Cancer Res. 2024;30:3798-3811.
    PubMed     Abstract available
    
    
    August 2024
58. KOBAN MU, Hartmann M, Amexis G, Franco P, et al
    Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741.
    PubMed     Abstract available
    
    
    
59. OH S, Koh J, Kim TM, Kim S, et al
    Transcriptomic heterogeneity of EGFR-mutant non-small cell lung cancer evolution towards small cell lung cancer.
    Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-0160.
    PubMed     Abstract available
    
    
    July 2024
60. REINMUTH N, Juan-Vidal O, Kowalski D, Bryl M, et al
    Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-24-0013.
    PubMed     Abstract available
    
    
    
61. SUVILESH KN, Manjunath Y, Nussbaum YI, Gadelkarim M, et al
    Targeting AKR1B10 by drug repurposing with epalrestat overcomes chemoresistance in non-small cell lung cancer patient-derived tumor organoids.
    Clin Cancer Res. 2024 Jul 17. doi: 10.1158/1078-0432.CCR-23-3980.
    PubMed     Abstract available
    
    
    
62. SCALERA S, Ricciuti B, Marinelli D, Mazzotta M, et al
    Transcriptional phenocopies of deleterious KEAP1 mutations correlate with survival outcomes in lung cancer treated with immunotherapy.
    Clin Cancer Res. 2024 Jul 9. doi: 10.1158/1078-0432.CCR-24-0626.
    PubMed     Abstract available
    
    
    
63. YANG SR, Jayakumaran G, Benhamida J, Febres-Aldana CA, et al
    Diffuse Pleural Mesotheliomas with Genomic Near-Haploidization: A Newly Recognized Subset with Distinct Clinical, Histologic, and Molecular Features.
    Clin Cancer Res. 2024;30:2780-2789.
    PubMed     Abstract available
    
    
    June 2024
64. CHOUDHURY NJ, Lai WV, Makhnin A, Heller G, et al
    A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small cell lung cancer.
    Clin Cancer Res. 2024 Jun 28. doi: 10.1158/1078-0432.CCR-23-3383.
    PubMed     Abstract available
    
    
    
65. BARBATO MI, Bradford D, Ren Y, Aungst SL, et al
    FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
    Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949.
    PubMed     Abstract available
    
    
    
66. PANG L, Huang Y, Zhuang W, Zhang Y, et al
    Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.
    Clin Cancer Res. 2024;30:2636-2646.
    PubMed     Abstract available
    
    
    
67. DALAL B, Tada T, Patel DP, Pine SR, et al
    Urinary Metabolite Diagnostic and Prognostic Liquid Biopsy Biomarkers of Lung Cancer in Non-smokers and Tobacco Smokers.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0637.
    PubMed     Abstract available
    
    
    
68. ROLFO CD, Madison RW, Pasquina LW, Brown DW, et al
    Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.
    Clin Cancer Res. 2024;30:2452-2460.
    PubMed     Abstract available
    
    
    May 2024
69. FUKUDA A, Okuma Y
    From Rarity to Reality: Osimertinib's Promising Horizon in Treating Uncommon EGFR Mutations in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2024 May 20. doi: 10.1158/1078-0432.CCR-23-4035.
    PubMed     Abstract available
    
    
    
70. PENG X, Zhao H, Ye L, Hou F, et al
    Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics.
    Clin Cancer Res. 2024 May 9. doi: 10.1158/1078-0432.CCR-23-3806.
    PubMed     Abstract available
    
    
    
71. REKHTMAN N
    All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC.
    Clin Cancer Res. 2024;30:1708-1711.
    PubMed     Abstract available
    
    
    
72. MARINIELLO A, Nasti TH, Chang DY, Hashimoto M, et al
    Platinum-Based Chemotherapy Attenuates the Effector Response of CD8 T Cells to Concomitant PD-1 Blockade.
    Clin Cancer Res. 2024;30:1833-1845.
    PubMed     Abstract available
    
    
    April 2024
73. ZHOU R, Liu F, Zhang H, Wang D, et al
    Fraction dose escalation of hypofractionated radiotherapy with concurrent chemotherapy and subsequent consolidation immunotherapy in locally advanced non-small cell lung cancer: a phase 1 study.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-23-3600.
    PubMed     Abstract available
    
    
    
74. ZUGAZAGOITIA J, Osma H, Baena J, Ucero AC, et al
    Facts and hopes on cancer immunotherapy for small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-1159.
    PubMed     Abstract available
    
    
    
75. PERESSINI M, Garcia-Campelo R, Massuti B, Marti C, et al
    Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-24-0104.
    PubMed     Abstract available
    
    
    
76. GRAZINI U, Markovets A, Ireland L, O'Neill D, et al
    Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2540.
    PubMed     Abstract available
    
    
    
77. OH HJ, Bae SC, Oh IJ, Park CK, et al
    Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Clin Cancer Res. 2024;30:1478-1487.
    PubMed     Abstract available
    
    
    
78. LEE EJ, Oh SY, Lee YW, Kim JY, et al
    Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Clin Cancer Res. 2024;30:1582-1594.
    PubMed     Abstract available
    
    
    
79. SINGH AK, Lewis CD, Boas CAWV, Diebolder P, et al
    Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.
    Clin Cancer Res. 2024;30:1293-1306.
    PubMed     Abstract available
    
    
    
80. VAIDYA P, Cohen EEW
    Facts and Hopes in Neoadjuvant Immunotherapy: Current Approvals and Emerging Evidence.
    Clin Cancer Res. 2024;30:1232-1239.
    PubMed     Abstract available
    
    
    February 2024
81. ZHOU I, Plana D, Palmer AC
    Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
    Clin Cancer Res. 2024;30:786-792.
    PubMed     Abstract available
    
    
    
82. KASI PM, Lee JK, Pasquina LW, Decker B, et al
    Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
    Clin Cancer Res. 2024;30:836-848.
    PubMed     Abstract available
    
    
    
83. WEI D, Wang L, Zuo X, Maitra A, et al
    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
    Clin Cancer Res. 2024;30:655-662.
    PubMed     Abstract available
    
    
    
84. WANG H, Chen Y, Wang X, Huang B, et al
    Germline mutations of Holliday junction resolvase genes in multiple primary malignancies involving lung cancer lead to PARP inhibitor sensitization.
    Clin Cancer Res. 2024 Feb 13. doi: 10.1158/1078-0432.CCR-22-3300.
    PubMed     Abstract available
    
    
    
85. VAN DE HAAR J, Mankor JM, Hummelink K, Monkhorst K, et al
    Combining genomic biomarkers to guide immunotherapy in non-small cell lung cancer.
    Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-4027.
    PubMed     Abstract available
    
    
    
86. LAKHANI NJ, Rasco D, Wang H, Men L, et al
    First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
    Clin Cancer Res. 2024;30:506-521.
    PubMed     Abstract available
    
    
    January 2024
87. PARRA ER, Zhang J, Duose DY, Gonzalez-Kozlova E, et al
    Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial.
    Clin Cancer Res. 2024 Jan 26. doi: 10.1158/1078-0432.CCR-23-0251.
    PubMed     Abstract available
    
    
    
88. GUAN S, Chen X, Wei Y, Wang F, et al
    Germline USP36 mutation confers resistance to EGFR-TKIs by upregulating MLLT3 expression in non-small cell lung cancer patients.
    Clin Cancer Res. 2024 Jan 23. doi: 10.1158/1078-0432.CCR-23-2357.
    PubMed     Abstract available
    
    
    
89. KESARI S, Wagle N, Carrillo JA, Sharma A, et al
    Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
    Clin Cancer Res. 2024;30:323-333.
    PubMed     Abstract available
    
    
    
90. NG J, Cai L, Girard L, Prall OWJ, et al
    Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Clin Cancer Res. 2024 Jan 5:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-2360.
    PubMed     Abstract available
    
    
    
91. NAKAMICHI S, Kubota K, Misumi T, Kondo T, et al
    Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study).
    Clin Cancer Res. 2024 Jan 2. doi: 10.1158/1078-0432.CCR-23-2568.
    PubMed     Abstract available
    
    
    December 2023
92. LOPEZ DE RODAS M, Wang Y, Peng G, Gu J, et al
    Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
    Clin Cancer Res. 2023 Dec 21. doi: 10.1158/1078-0432.CCR-23-2457.
    PubMed     Abstract available
    
    
    
93. PASSIGLIA F, Righi L, Bironzo P, Listi A, et al
    Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial.
    Clin Cancer Res. 2023 Dec 18. doi: 10.1158/1078-0432.CCR-23-2431.
    PubMed     Abstract available
    
    
    
94. BOUMELHA J, Molina-Arcas M, Downward J
    Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
    Clin Cancer Res. 2023;29:5012-5020.
    PubMed     Abstract available
    
    
    
95. HUMMELINK K, Tissier R, Bosch LJW, Krijgsman O, et al
    A dysfunctional T cell gene signature for predicting non-response to PD-1 blockade in non-small cell lung cancer that is suitable for routine clinical diagnostics.
    Clin Cancer Res. 2023 Dec 13. doi: 10.1158/1078-0432.CCR-23-1061.
    PubMed     Abstract available
    
    
    
96. ROLFO C, Russo A
    In search of lost biomarker for immunotherapy in small-cell lung cancer.
    Clin Cancer Res. 2023 Dec 12. doi: 10.1158/1078-0432.CCR-23-3087.
    PubMed     Abstract available
    
    
    
97. BESSEDE A, Peyraud F, Besse B, Cousin S, et al
    TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2566.
    PubMed     Abstract available
    
    
    
98. VOKES NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, et al
    ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
    Clin Cancer Res. 2023;29:4958-4972.
    PubMed     Abstract available
    
    
    November 2023
99. MURRAY JC, Sivapalan L, Hummelink K, Balan A, et al
    Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1469.
    PubMed     Abstract available
    
    
    October 2023
100. HERBST RS, Blanke CD, Sigal EV
     Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships.
     Clin Cancer Res. 2023 Oct 30. doi: 10.1158/1078-0432.CCR-23-2690.
     PubMed     Abstract available
     
     
     
101. PAZ-ARES L, Garassino MC, Chen Y, Reinmuth N, et al
     Durvalumab +/- tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.
     Clin Cancer Res. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1689.
     PubMed     Abstract available
     
     
     September 2023
102. BESSEDE A, Peyraud F, Le Moulec S, Cousin S, et al
     Upregulation of Indoleamine 2,3-dioxygenase 1 in tumor cells and tertiary lymphoid structures is a hallmark of inflamed non-small cell lung cancer.
     Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-1928.
     PubMed     Abstract available
     
     
     
103. DIMOU A
     Time to Think About Human Leukocyte Antigen-Based Diagnostics in Lung Cancer?
     Clin Cancer Res. 2023 Sep 26. doi: 10.1158/1078-0432.CCR-23-2152.
     PubMed     Abstract available
     
     
     
104. SOLTA A, Boettiger K, Kovacs I, Lang C, et al
     Entinostat enhances the efficacy of chemotherapy in small cell lung cancer through S-phase arrest and decreased base excision repair.
     Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-1795.
     PubMed     Abstract available
     
     
     
105. CANTOR DJ, Aggarwal C
     Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond.
     Clin Cancer Res. 2023;29:3563-3565.
     PubMed     Abstract available
     
     
     
106. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
     Clin Cancer Res. 2023;29:3573-3578.
     PubMed     Abstract available
     
     
     
107. ABEL ML, Takahashi N, Peer C, Redon CE, et al
     Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial.
     Clin Cancer Res. 2023;29:3603-3611.
     PubMed     Abstract available
     
     
     
108. PELLINI B, Madison RW, Childress M, Miller ST, et al
     Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2023 Sep 13. doi: 10.1158/1078-0432.CCR-23-1578.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.